These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25080279)

  • 1. Injectable testosterone undecanoate for the treatment of hypogonadism.
    Corona G; Maseroli E; Maggi M
    Expert Opin Pharmacother; 2014 Sep; 15(13):1903-26. PubMed ID: 25080279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
    Yassin DJ; Doros G; Hammerer PG; Yassin AA
    J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
    Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
    J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.
    Aversa A; Bruzziches R; Francomano D; Spera G; Lenzi A
    J Endocrinol Invest; 2010 Dec; 33(11):776-83. PubMed ID: 20220293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
    Aversa A; Bruzziches R; Francomano D; Rosano G; Isidori AM; Lenzi A; Spera G
    J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone undecanoate in the treatment of male hypogonadism.
    Edelstein D; Basaria S
    Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
    J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome.
    Park MG; Yeo JK; Cho DY; Kim JW; Kim JW; Oh MM; Kim JJ; Moon du G
    J Sex Med; 2015 Apr; 12(4):966-74. PubMed ID: 25648342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
    Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
    J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    Andrology; 2017 Sep; 5(5):905-913. PubMed ID: 28771964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.
    Corona G; Rastrelli G; Morgentaler A; Sforza A; Mannucci E; Maggi M
    Eur Urol; 2017 Dec; 72(6):1000-1011. PubMed ID: 28434676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study.
    Haider KS; Haider A; Doros G; Traish A
    J Urol; 2018 Jan; 199(1):257-265. PubMed ID: 28728990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.
    Jockenhövel F; Minnemann T; Schubert M; Freude S; Hübler D; Schumann C; Christoph A; Ernst M
    Eur J Endocrinol; 2009 May; 160(5):815-9. PubMed ID: 19225035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Waist circumference is superior to weight and BMI in predicting sexual symptoms, voiding symptoms and psychosomatic symptoms in men with hypogonadism and erectile dysfunction.
    Yassin AA; Nettleship JE; Salman M; Almehmadi Y
    Andrologia; 2017 May; 49(4):. PubMed ID: 27400881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
    J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
    Permpongkosol S; Tantirangsee N; Ratana-olarn K
    J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.